Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories

Page 2

AltPep unpacks $23.1m round
University of Washington spinout AltPep will use the money to advance work on its lead asset that targets Alzheimer’s disease.
J-Pharma jacks series D up to $21m
Fidelity provided a $4.8m second tranche after a first close featuring vehicles for Kyushu University and Osaka University.
Everactive nails down $35m
University of Michigan and Virginia-founded Everactive has reached its series C target after three tranches.
SpyGlass observes $27.5m
The eye disease device developer has raised series B funding to advance research originating from University of Colorado's s Sue Anschutz-Rodgers Eye Center.
Neuros Medical implants $38.5m
CWRU‘s pain neurostimulation spinout has secured series BB funding ahead of a 180-patient trial.
First Light switches on $25m
OSI has reinvested in the Oxford fusion energy spinout now set to expand its R&D capacity and headcount.
Exo Therapeutics executes $25m series A
The exosite drug developer has launched publicly to advance research from Harvard University and Salk Institute for Biological Studies. decodes $32m
Stanford-StartX Fund has backed in a series B round that boosted the software developer sourcing platform’s overall funding to at least $46m.
InnoSkel sets out with $24.3m
Spun out of University of Côte d’Azur and Inserm, InnoSkel expects to fund clinical work to address a form of skeletal dysplasia that causes dwarfism.
Deepcell caps $20m series A
Stanford University supplied capital to help its AI cell analysis spinout Deepcell close its second funding round.

test reg